Shares of US biotech firm Medivation (Nasdaq: MDVN) fell 2.48% to $38.16 yesterday, despite the company reporting positive news on the development of its blood cancer drug candidate.
The company announced that the US Food and Drug Administration has lifted the partial clinical hold on the Investigational New Drug (IND) application for pidilizumab (MDV9300) in hematological malignancies and confirmed that the Phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), as well as other studies that cross reference the IND, may now proceed. The partial clinical hold was not related to any safety concerns.
Medivation acquired rights to pidiluzumab from CureTech under a $355 million deal in 2014, after Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) pulled out of a collaboration with the company (The Pharma Letter February 1, 2013).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze